Abstract
Objectives: Estimate the probabilities, for Alzheimer's disease (AD) patients, of transitioning between stages of disease severity (mild, moderate, severe, dead) and care settings (community, institutional). Methods: Data were compiled by the National Alzheimer Coordinating Center. The main analyses were limited to 3,852 patients who were >50 years old, diagnosed with possible/probable AD and had at least two center visits. A multinomial logistic model accounting for patient and center level correlation was used to calculate transition probabilities between stages of the Clinical Dementia Rating (CDR). Separately we calculated the probabilities of being institutionalized based on CDR stage. Both analyses controlled for baseline age, time between visits, sex, marital status, whether white, whether Hispanic and number of years of education. Results: The annual probabilities of dying for patients in mild, moderate and severe health states were 5.5%, 21.5% and 48.0%, respectively, while the annual probabilities for institutionalization were 1.2%, 3.4% and 6.6%, respectively. The majority of mild and moderate patients remain in the same health state after one year, 77.4% and 50.1% respectively. Progressing patients are most likely to transition one stage, but 1.3% of mild patients become severe in one year. Some patients revert to lower severity stages, 7% from moderate to mild. Conclusions: Transition probabilities to higher CDR stages and to institutionalization are lower than those published previously, but the probability of death is higher. These results are useful for understanding AD progression and can be used in simulation models to evaluate costs and compare new treatments or policies.
Keywords: Alzheimer disease, Natural history study, Progression, Transition probabilities, cholinesterase inhibitor, multinomial regressions, pharmaceutical treatments.
Current Alzheimer Research
Title:Measuring Alzheimer Disease Progression with Transition Probabilities: Estimates from NACC-UDS
Volume: 9 Issue: 9
Author(s): D. Eldon Spackman, Srikanth Kadiyala, Peter J. Neumann, David L. Veenstra and Sean D. Sullivan
Affiliation:
Keywords: Alzheimer disease, Natural history study, Progression, Transition probabilities, cholinesterase inhibitor, multinomial regressions, pharmaceutical treatments.
Abstract: Objectives: Estimate the probabilities, for Alzheimer's disease (AD) patients, of transitioning between stages of disease severity (mild, moderate, severe, dead) and care settings (community, institutional). Methods: Data were compiled by the National Alzheimer Coordinating Center. The main analyses were limited to 3,852 patients who were >50 years old, diagnosed with possible/probable AD and had at least two center visits. A multinomial logistic model accounting for patient and center level correlation was used to calculate transition probabilities between stages of the Clinical Dementia Rating (CDR). Separately we calculated the probabilities of being institutionalized based on CDR stage. Both analyses controlled for baseline age, time between visits, sex, marital status, whether white, whether Hispanic and number of years of education. Results: The annual probabilities of dying for patients in mild, moderate and severe health states were 5.5%, 21.5% and 48.0%, respectively, while the annual probabilities for institutionalization were 1.2%, 3.4% and 6.6%, respectively. The majority of mild and moderate patients remain in the same health state after one year, 77.4% and 50.1% respectively. Progressing patients are most likely to transition one stage, but 1.3% of mild patients become severe in one year. Some patients revert to lower severity stages, 7% from moderate to mild. Conclusions: Transition probabilities to higher CDR stages and to institutionalization are lower than those published previously, but the probability of death is higher. These results are useful for understanding AD progression and can be used in simulation models to evaluate costs and compare new treatments or policies.
Export Options
About this article
Cite this article as:
Eldon Spackman D., Kadiyala Srikanth, J. Neumann Peter, L. Veenstra David and D. Sullivan Sean, Measuring Alzheimer Disease Progression with Transition Probabilities: Estimates from NACC-UDS, Current Alzheimer Research 2012; 9 (9) . https://dx.doi.org/10.2174/156720512803569046
DOI https://dx.doi.org/10.2174/156720512803569046 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Probabilistic Cost-Effectiveness Analysis of Vaccination for Mild or Moderate Alzheimer’s Disease
Current Alzheimer Research The Double Roles of the Prostaglandin E<sub>2</sub> EP2 Receptor in Intracerebral Hemorrhage
Current Drug Targets Aporphines and Parkinson’s Disease: Medical Tools for the Future
Current Topics in Medicinal Chemistry Coping with Stress During Aging: The Importance of a Resilient Brain
Current Neuropharmacology Chemoinformatics Approaches for Traditional Chinese Medicine Research and Case Application in Anticancer Drug Discovery
Current Drug Discovery Technologies A Clinical Perspective: Anti Taus Treatment in Alzheimers Disease
Current Alzheimer Research Role of Metals in Neuronal Apoptosis: Challenges Associated with Neurodegeneration
Current Alzheimer Research Patent Selections
Recent Patents on DNA & Gene Sequences Immunological Therapeutic and Imaging Approaches for Prion Disease
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents An Introduction to the Nutrition and Metabolism of Choline
Central Nervous System Agents in Medicinal Chemistry Regular Physical Activity and Vascular Aging
Current Pharmaceutical Design Kynurenine Pathway and Disease: An Overview
CNS & Neurological Disorders - Drug Targets Donepezil: An Important Prototype to the Design of New Drug Candidates for Alzheimer’s Disease
Mini-Reviews in Medicinal Chemistry A Summary of Electrospun Nanofibers as Drug Delivery System: Drugs Loaded and Biopolymers Used as Matrices
Current Drug Delivery Sensory-Motor Integration in the Medial Medulla
Current Neuropharmacology Medical Music Therapy Based on Baby Science (Baby-Science-Based Music Therapy) and Assistive Technology for Children
Current Pediatric Reviews Galantamine-based Hybrid Molecules with Acetylcholinesterase, Butyrylcholinesterase and γ-Secretase Inhibition Activities
Current Alzheimer Research Anesthesia, Calcium Homeostasis and Alzheimers Disease
Current Alzheimer Research Advances in Stem Cells Transplantation for the Therapy of Parkinson’s Disease
Current Stem Cell Research & Therapy Neuroprotective Effects of Quercetin: From Chemistry to Medicine
CNS & Neurological Disorders - Drug Targets